Article
Clinical Neurology
Kanita Dervic, Leo Sher, Hanga C. Galfalvy, Michael Grunebaum, Ainsley K. Burke, Gregory Sullivan, M. Elizabeth Sublette, J. John Mann, Maria A. Oquendo
Summary: In bipolar patients, lithium has a greater effect in preventing suicidal behavior in individuals over 42 years old. Lithium significantly reduces the risk of suicidal behavior compared to valproate in older patients (>42 years old) or younger patients on either medication. This effect is independent of clinical and sociodemographic characteristics.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Article
Pharmacology & Pharmacy
Zi-bin Jin, Zhuo Wu, Yi-fan Cui, Xue-peng Liu, Hong-bo Liang, Jia-yong You, Chen-yu Wang
Summary: This study aimed to analyze the pharmacokinetics of lithium and investigate the impact of patient characteristics on the drug's clearance. The results showed that weight, creatinine clearance, and total daily dose of lithium can affect the drug's clearance, suggesting the need for individualized dosing regimens for patients with bipolar disorder.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Multidisciplinary Sciences
Erdem Pulcu, Kate E. A. Saunders, Catherine J. Harmer, Paul J. Harrison, Guy M. Goodwin, John R. Geddes, Michael Browning
Summary: The affective variability of bipolar disorder (BD) is different from that of borderline personality disorder (BPD), and lithium treatment increases the volatility of positive affect.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Biochemistry & Molecular Biology
Himanshu K. Mishra, Noelle M. Ying, Angelica Luis, Heather Wei, Metta Nguyen, Timothy Nakhla, Sara Vandenburgh, Martin Alda, Wade H. Berrettini, Kristen J. Brennand, Joseph R. Calabrese, William H. Coryell, Mark A. Frye, Fred H. Gage, Elliot S. Gershon, Melvin G. McInnis, Caroline M. Nievergelt, John I. Nurnberger, Paul D. Shilling, Ketil J. Oedegaard, Peter P. Zandi, R. Kelsoe John, David K. Welsh, Michael J. McCarthy
Summary: Neuronal circadian rhythm abnormalities are present in patients with bipolar disorder, with the most pronounced deficits observed in individuals who do not respond to lithium treatment. Stimulation of entrainment pathways may partly reverse these rhythm deficits.
MOLECULAR PSYCHIATRY
(2021)
Article
Clinical Neurology
Yian Lin, Adam X. Maihofer, Emma Stapp, Megan Ritchey, Ney Alliey-Rodriguez, Amit Anand, Yokesh Balaraman, Wade H. Berrettini, Holli Bertram, Abesh Bhattacharjee, Cynthia V. Calkin, Carla Conroy, William Coryell, Nicole D'Arcangelo, Anna DeModena, Joanna M. Biernacka, Carrie Fisher, Nicole Frazier, Mark Frye, Keming Gao, Julie Garnham, Elliot Gershon, Kara Glazer, Fernando S. Goes, Toyomi Goto, Elizabeth Karberg, Gloria Harrington, Petter Jakobsen, Masoud Kamali, Marisa Kelly, Susan G. Leckband, Falk W. Lohoff, Andrea Stautland, Michael J. McCarthy, Melvin G. McInnis, Francis Mondimore, Gunnar Morken, John I. Nurnberger, Ketil J. Oedegaard, Vigdis Elin Giever Syrstad, Kelly Ryan, Martha Schinagle, Helle Schoeyen, Ole A. Andreassen, Marth Shaw, Paul D. Shilling, Claire Slaney, Bruce Tarwater, Joseph R. Calabrese, Martin Alda, Caroline M. Nievergelt, Peter P. Zandi, John R. Kelsoe
Summary: The study aimed to identify predictors of lithium response in bipolar disorder, and found several clinical features associated with failure to respond to lithium. More research is needed to confirm these clinical predictors of treatment failure and to determine their clinical utility in differentiating who will respond well to lithium before starting pharmacotherapy.
Article
Pharmacology & Pharmacy
Rachel Shvartsur, Galila Agam, Alla Shnaider, Sarit Uzzan, Ahmad Nassar, Adi Jabarin, Naim Abu-Freha, Karen Meir, Abed N. Azab
Summary: Chronic low-dose aspirin can mitigate the typical renal side effects of standard-dose lithium and enhance the beneficial behavioral effects of low-dose lithium therapy without aggravating its toxicity.
Article
Psychiatry
Keita Idemoto, Tomihisa Niitsu, Tatsuki Hata, Tamaki Ishima, Sumiko Yoshida, Kotaro Hattori, Tadasu Horai, Ikuo Otsuka, Hidenaga Yamamori, Shigenobu Toda, Yosuke Kameno, Kiyomitsu Ota, Yasunori Oda, Atsushi Kimura, Tasuku Hashimoto, Norio Mori, Mitsuru Kikuchi, Yoshio Minabe, Ryota Hashimoto, Akitoyo Hishimoto, Kazuyuki Nakagome, Kenji Hashimoto, Masaomi Iyo
Summary: The study revealed that serum levels of glial cell line-derived neurotrophic factor (GDNF) were significantly decreased in patients with bipolar disorder (BD) and major depressive disorder (MDD) compared to healthy controls, and remained lower in patients in remission or depressive states after treatment. Furthermore, lower serum GDNF levels were associated with a higher clinical severity and better response to lithium therapy in BD patients.
PSYCHIATRY RESEARCH
(2021)
Review
Psychiatry
Zainab Nabi, Jacki Stansfeld, Martin Ploderl, Lisa Wood, Joanna Moncrieff
Summary: This study is a systematic review and meta-analysis that includes all eligible data and evaluates the effect of lithium on suicide, non-fatal suicidal behavior, and suicide attempts. The results suggest that evidence from randomized trials is inconclusive and does not support the idea that lithium prevents suicide or suicidal behavior.
EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES
(2022)
Article
Clinical Neurology
Lars Vedel Kessing, Simon Christoffer Ziersen, Thomas Gerds, Esben Budtz-Jorgensen
Summary: This nationwide population-based longitudinal register linkage study aimed to investigate the long-term response to lithium in patients with bipolar disorder with and without comorbid epilepsy. The study also aimed to compare differences in responses between lithium, valproate, and lamotrigine within patients with comorbid bipolar disorder and epilepsy. The findings suggest that valproate and lamotrigine should be given priority in these patients.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Article
Psychiatry
Amir Garakani, Frank D. Buono, Kaitlyn Larkin, Maxim Polonsky, Joseph F. Goldberg
Summary: This study adapted a standardized measure of obsessive-compulsive thinking to assess chronic suicidal ideation in patients with mood disorder, finding that the tool is internally consistent and reliable.
JOURNAL OF PSYCHIATRIC RESEARCH
(2022)
Review
Neurosciences
Janusz K. Rybakowski, Ewa Ferensztajn-Rochowiak
Summary: This mini-review highlights the contradiction between the positive therapeutic data of lithium and its decreased global usage. Lithium has been proven to be the best mood stabilizer in maintaining bipolar disorder, preventing manic and depressive recurrences. It is also promising in augmenting the treatment of resistant depression and has additional benefits such as antisuicidal, antiviral, immunomodulatory, and neuroprotective effects. However, the decline in lithium usage in many countries can be attributed to the promotion of other mood stabilizers and concerns over its side effects. Efforts have been made to challenge the negative perception of lithium and optimize its long-term administration.
NEUROSCIENCE LETTERS
(2022)
Letter
Clinical Neurology
Mustafa Akkus
Summary: This case suggests that lithium-induced tardive dyskinesia may be reversible in a dose-dependent manner.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Article
Neuroimaging
Joseph J. Shaffer, Virginia Willour, Jess G. Fiedorowicz, Gary E. Christensen, Jeffrey D. Long, Casey P. Johnson, Samantha L. Schmitz, Aislinn J. Williams, John Wemmie, Vincent A. Magnotta
Summary: This study explored the relationship between suicide attempts and brain imaging measures in bipolar disorder, finding differences in brain activation and metabolism associated with suicide attempts. The study also revealed that the number of suicide attempts was related to differences in brain regions, indicating different neurobiological underpinnings for suicide history and number of attempts.
BRAIN IMAGING AND BEHAVIOR
(2022)
Article
Psychiatry
Jane E. Persons, Paul Lodder, William H. Coryell, John Nurnberger, Jess G. Fiedorowicz
Summary: This study found that manic and anxiety symptoms did not significantly contribute to suicidal ideation and behavior in individuals with bipolar disorder during a depressive state, with the main risk factor being severe depressive symptoms. The limitations of small sample size and measurement tools may have influenced these findings, suggesting future studies would benefit from larger samples and more rigorous assessments.
PSYCHIATRY RESEARCH
(2022)
Article
Psychology, Clinical
Erika F. H. Saunders, Dahlia Mukherjee, Daniel A. Waschbusch, Duanping Liao, Amanda M. Pearl, Errol Aksu, Edward O. Bixler
Summary: The use of structured interviews helped physicians identify major depressive disorder by the second visit in patients with complex psychopathology. Patients with high complexity/severity of symptoms and more difficulty with functioning were less commonly identified with bipolar disorder even with the assistance of a structured interview.Structured assessment tools may improve the detection of psychiatric illness by clinicians at the first visit.
DEPRESSION AND ANXIETY
(2021)